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Autosomal dominant cerebellar ataxia (ADCA) is a group of heterogeneous neurodegenerative disorders. By po-
sitional cloning, we have identified the gene strongly associated with a form of degenerative ataxia (chromosome
16q22.1–linked ADCA) that clinically shows progressive pure cerebellar ataxia. Detailed examination by use of
audiogram suggested that sensorineural hearing impairment may be associated with ataxia in our families. After
restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52
unrelated Japanese families harbor a heterozygous CrT single-nucleotide substitution, 16 nt upstream of the putative
translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called “puratrophin-
1” (Purkinje cell atrophy associated protein-1). The full-length puratrophin-1 mRNA had an open reading frame
of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide
exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of
puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus. Puratrophin-1—normally ex-
pressed in a wide range of cells, including epithelial hair cells in the cochlea—was aggregated in Purkinje cells of
the chromosome 16q22.1–linked ADCA brains. Consistent with the protein prediction data of puratrophin-1, the
Golgi-apparatus membrane protein and spectrin also formed aggregates in Purkinje cells. The present study high-
lights the importance of the 5′ untranslated region (UTR) in identification of genes of human disease, suggests that
a single-nucleotide substitution in the 5′ UTR could be associated with protein aggregation, and indicates that the
GEF protein is associated with cerebellar degeneration in humans.
Introduction
Autosomal dominant cerebellar ataxia (ADCA) is a clini-
cal entity of heterogeneous neurodegenerative diseases
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that show dominantly inherited, progressive cerebellar
ataxia that can be variably associated with other neu-
rological and systemic features (Harding 1982). Circum-
scribed groups of neurons in the cerebellum, brainstem,
basal ganglia, or spinal cord are selectively involved in
different combinations and to varying extents among
diseases (Graham and Lantos 2002). ADCA is now clas-
sified by the responsible mutations or gene loci. To date,
24 subtypes have been identified: spinocerebellar ataxia
type (SCA) 1, 2, 3 (or, Machado-Joseph disease [MJD]),
4–8, 10–19/22, 21, 23, 25, 26; dentatorubral and pal-
lidoluysian atrophy (DRPLA); and ADCA with muta-
tion in fibroblast growth factor (FGF) 14 (Stevanin et
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al. 2000, 2004; Margolis 2002; van Swieten et al. 2003;
Yu et al. 2005). Among these, mutations in SCA1, SCA2,
SCA3/MJD, SCA6, SCA7, SCA17, and DRPLA have
been identified as the expansion of a trinucleotide (CAG)
repeat that encodes the polyglutamine tract, uniformly
causing aggregation of polyglutamine-containing causa-
tive protein (Ross and Poirier 2004). Expansion of non-
coding trinucleotide (CAG or CTG) or pentanucleotide
(ATTCT) repeats are involved in SCA8, SCA10, and
SCA12 (Holmes et al. 1999; Koob et al. 1999; Matsuura
et al. 2000). Very few families are affected by missense
mutations in the protein kinase Cg (PKCg) (SCA14 [see
Chen et al. 2003]) and FGF14 genes (ADCA with FGF14
mutation [see van Swieten et al. 2003]). However, genes
or even their loci remain unidentified for 120%–40%
of families with ADCA (Sasaki et al. 2003).
We had previously mapped mutations in six Japanese
families with ADCA to a 10-cM interval in human chro-
mosome 16q13.1-q22.1, identifying 16q-linked ADCA
type III, or spinocerebellar ataxia 4 (SCA4 [MIM
600223]) (Ishikawa et al. 2000). Clinically, our families
show cerebellar ataxia without obvious evidence of ex-
tracerebellar neurological dysfunction (i.e., “pure cere-
bellar ataxia,” or “ADCA type III”) (Harding 1982;
Ishikawa et al. 2000). The average age at onset of ataxia
was 155 years (Ishikawa et al. 1997), which suggests
that this disease shows the oldest age at onset among
ADCA types with assigned loci. Another important clini-
cal feature of this disease is that a substantial number
of patients show progressive sensorineural hearing im-
pairment (Owada et al., in press). Since the hearing im-
pairment can be very mild and of later onset, presence
of hearing impairment can be easily overlooked. How-
ever, this finding may indicate that the mutated gene
could cause hearing impairment as well as ataxia. In this
sense, it would be more appropriate to use the term
“chromosome 16q22.1–linked ADCA” instead of
“ADCA type III” to describe our families. Neuropatho-
logical examination showed peculiar degeneration of
Purkinje cells that was not described in other degenera-
tive ataxias (Owada et al., in press). Many Purkinje cells
undergo shrinkage and are surrounded by amorphous
materials composed of Purkinje-cell somato-dendritic
sprouts and an increased number of presynaptic ter-
minals. These findings may indicate that certain proteins
involved in the cytoskeleton of Purkinje cells are dis-
turbed in chromosome 16q22.1–linked ADCA.
Chromosome 16q22.1–linked ADCA has been as-
signed to the same locus as another ADCA, SCA4 (Flan-
igan et al. 1996; Hellenbroich et al. 2003). Although
SCA4 and chromosome 16q22.1–linked ADCA may be
allelic, SCA4 is clinically distinct from chromosome
16q22.1–linked ADCA, because SCA4 shows promi-
nent sensory axonal neuropathy and pyramidal tract
signs, with an age at onset earlier than that of chromo-
some 16q22.1–linked ADCA (Flanigan et al. 1996; Hel-
lenbroich et al. 2003). Several groups, including ours,
have refined the loci of SCA4/chromosome 16q22.1–
linked ADCA and have, so far, excluded repeat expan-
sions as mutations (Hellenbroich et al. 2003; Li et al.
2003; Hirano et al. 2004). The minimum candidate re-
gion of SCA4 and chromosome 16q22.1–linked ADCA
is set at the region between markers D16S3031 and
D16S3095. A strong founder effect has been observed
for chromosome 16q22.1–linked ADCA (Li et al. 2003),
which indicates the need to recruit a large number of
families to narrow the critical region.
To discover the causative gene of chromosome
16q22.1–linked ADCA, we embarked on a positional
cloning study by recruiting 52 families from diverse
regions of Japan. Here, we describe the identification of
a strong association between a single-nucleotide change
and chromosome 16q22.1–linked ADCA and show the
consequence of this genetic change on mRNA and pro-
tein levels. The data presented here also suggest that a
single-nucleotide change in the 5′ UTR could be asso-
ciated with aggregation of the gene product.
Patients, Material, and Methods
Recruitment of Families with Chromosome
16q22.1–Linked ADCA
We attempted to include families clinically diagnosed
with late-onset ADCA type III from a wide region of
Japan. Fifty-two families, including 109 affected indi-
viduals and 48 at-risk individuals, were ultimately re-
cruited. These families originated from seven of eight
districts of Japan (Hokkaido, Tohoku, Kanto, Chu-bu,
Kinki, Chu-goku, and Kyu-shu), which indicates that
their origins are widespread. Clinical features of these
patients were consistent with those of families described
elsewhere (Ishikawa et al. 1997, 2000; Li et al. 2003).
Detailed neuro-otological examinations, including
pure-tone audiometry, were performed on 13 families at
the Departments of Neurology and Otolaryngology, To-
kyo Medical and Dental University. Progressive hearing
impairment was assessed when the pure-tone average
calculated from thresholds at the frequencies of 0.5, 1,
and 2 kHz was more severe than the mean 2 SD of
age-matched normal Japanese population (Tsuiki et al.
2002). By that criterion, 6 (42.9%) of 14 families had a
hearing impairment other than age-related hearing loss.
When we used the recommendations for the description
of genetic and audiological data composed by the GEN-
DEAG study group (see The Hereditary Hearing Loss
Homepage), all of the patients with the hearing impair-
ment were confirmed to have bilateral sensorineural
hearing loss of mild-to-moderate severity. The audio-
metric configurations of these patients include mid-fre-
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Table 1
Microsatellite Markers and Primer Sequences
The table is available in its entirety in the online edition
of The American Journal of Human Genetics.
quency U-shaped, flat, and high-frequency sloping. These
data would suggest that the hearing impairment in our
families is not a coincidence.
Preparation of DNA and RNA Samples
After informed consent was obtained, genomic DNA
was extracted from peripheral-blood lymphocytes or
lymphoblastoid cell lines by use of methods described
elsewhere (Ishikawa et al. 1997). All families were ex-
cluded for SCA1, SCA2, SCA3/MJD, SCA6, SCA7,
SCA8, SCA12, SCA14, SCA17, and DRPLA by testing
mutations in the disease genes. For expression analysis
on an RNA level, frozen cerebellar tissues of four brains
affected with Alzheimer disease (AD) (age at death,
range 65–85 years; duration of the disease, range 5–10
years) were used as controls. Clinically, these patients
with AD showed a moderate-to-severe degree of demen-
tia, as measured by the Clinical Dementia Rating (Hughes
et al. 1982). Neuropathology in the cerebella of these
patients showed only a few senile plaques without neu-
ronal losses. For chromosome 16q22.1–linked ADCA,
two patients were studied (ages at death, 74 and 78
years). Both control and 16q22.1-linked ADCA brains
were obtained at autopsy, with the families’ written con-
sents approved by each institutional ethical committee.
These brains were immediately frozen and stored at
80C until use. Total RNA was extracted from frozen
cerebellar tissues as described elsewhere (Ishikawa et al.
1999). Poly-A RNA was selected from total RNA by
NucleoTrap (Macherey-Nagel).
Restriction of Candidate Interval by Genotyping
and Haplotype Analysis
Genotypes were determined for 23 informative mark-
ers, including five new markers we identified (GGAA10,
TTCC01, TA001, GA001, and AAT01 [GenBank ac-
cession numbers AB13610, AB13611, AB13612, AB1-
97662, and AB13613, respectively]) (table 1). Standard
PCR was performed in a final volume of 20 ml, con-
taining 10 ng of genomic DNA, 3.4 pmol of each primer,
2.5 mM of dNTP, and 0.75 U of Taq polymerase (Tak-
ara). Thermal cycling was performed at 94C for 5 min
for initial denaturing, 30 cycles of denaturation (94C
for 30 s), annealing (55C for 30 s), and extension (72C
for 30 s), followed by a final extension at 72C for 5
min in an ABI GeneAmp PCR system 9700 (PE Applied
Biosystems). The amplified product was separated in
the Automated Laser Fluorescent DNA Sequencer II
(Pharmacia Biotech), and genotypes were determined
with Fragment Manager (Pharmacia Biotech) (Ishikawa
et al. 1997). Allele frequencies in the general population
were analyzed in 500 unrelated individuals without per-
sonal or family history of ataxia or other degenerative
diseases.
Haplotypes of 16q22.1 markers were determined for
10 families (fig. 1) that were informative for determining
the phase of alleles. The remaining 42 families were not
sufficiently informative for determining the phase. Pau-
city of informative families was mainly due to the late
age at onset of this disease. For these uninformative fami-
lies, only combinations of genotypes were assessed, and
the region of genotypes shared with the larger 10 families
was compared.
Screening for Mutation in 21 Different Candidate
Genes
Within the most critical interval, 21 genes or clusters
of ESTs were retrieved from the Ensembl, UniGene, Na-
tional Center for Biotechnology Information (NCBI), and
Celera databases. Primers were designed to amplify in-
dividual exon and intron-exon boundaries for each gene,
and genomic DNA was amplified by the aforementioned
standard PCR protocol (primer sequences are available
on request). Amplicons from controls and patients were
first separated on 2% agarose gels, to determine by
screening whether any aberrant bands were amplified
from patient DNA samples. Residual solutions of PCR
products were then purified with QIAquick PCR puri-
fication kit (Qiagen) and were directly sequenced using
Applied Biosystems Model 377 or 3100 Automated Se-
quencer, as described elsewhere (Li et al. 2003). The
mutation was analyzed by comparing sequenced data and
annotated databases, with use of the software DNASIS
(Hitachi). Genomic rearrangement was screened by
Southern-blot analysis by use of cosmid clones for probe
synthesis as described elsewhere (Kobayashi et al. 1998).
In brief, cosmid clones, tandemly covering the chromo-
some 16q22.1–linked ADCA critical region, were gen-
erated by subcloning from the BAC contig (Li et al.
2003). Then, the radiolabeled (32P) probe was generated
from each cosmid clone. Genomic DNA extracted from
lymphoblastoid cell lines of control individuals and pa-
tients with chromosome 16q22.1–linked ADCA was di-
gested with a restriction enzyme and was subjected to
Southern-blot analysis. To screen gene arrangement,
analysis was performed with six different restriction en-
zymes (BamHI, BglII, EcoRI, EcoRV, HindIII, and
XbaI).
Twenty-one exons and 20 introns of the puratro-
phin-1 gene, partially annotated as “Q9H7K4,” were
sequenced entirely. The genomic region between the pur-
atrophin-1 gene and SLC9A5 was also screened (fig. 2).
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Figure 2 Positional cloning of the chromosome 16q22.1–linked ADCA gene. A, Genetic and physical maps of the interval in chromosome
16q22.1, showing microsatellite markers used to refine the interval. Twenty-one genes and their direction of transcription (Ensembl) are shown.
B, Nucleotide sequences of exon 1 flanking the CrT single-nucleotide change in control and patient DNA samples. The patient harbors a
heterozygous CrT substitution on the sense strand. C, RFLP by digestion with EcoNI. PCR was performed with primers UK1-E1F1 and UK1-
E1R1. Whereas the normal allele produces digested fragments of 209, 92, and 59 bp, the CrT change in the mutant allele disrupts one EcoNI
site, producing fragments of 268 and 92 bp.
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The CrT change in the 5′ UTR was detected by am-
plifying genomic DNA with forward primer UK1-E1F1
(5′-CAGCGCGGTTCACACTGAGA-3′) and reverse
primer UK1-E1R1 (5′-GGCCCTTTCTGACAGGAC-
TGA-3′), which yielded a specific product of 360 bp.
This amplicon harbors two EcoNI sites, one of which
is destroyed by the CrT change.
Expression Analysis of Puratrophin-1 mRNA by RT-PCR
To characterize puratrophin-1 mRNA in the human
brain, poly-ARNA obtained from control human cere-
bellar tissues was reverse transcribed with SuperScript
II (Stratagene), and the entire coding region was ampli-
fied with primers UKI-RT-025F (5′-TTCGCCTGCATTG-
CCCACTGAG-3′) and UK1-RT-005R (5′-CACACACA-
TCAGAAAGGGTAGTCAAC-3′), which yielded a ma-
jor product of 3,835 bp. To analyze alternative transcrip-
tion, the PCR products were subcloned into pCR2.1-
TOPO (Invitrogen), and 10 randomly selected clones
from each brain mRNA (2 AD and 2 chromosome
16q22.1–linked ADCA cerebella) were sequenced and
compared with partially annotated sequences (Q9H7K4,
NCBI accession numbers BC054486 and AK024475).
Rapid cloning of the 5′ and 3′ ends (5′- and 3′-RACE)
was performed using Marathon-ready cDNA kit (Clon-
tech [BD Biosciences]) as described elsewhere (Tsunemi
et al. 2002). The entire 5′ UTR was amplified with prim-
ers UK1-RT-493F (5′-TGAGACAGTCTCAGTCAGG-
TCAC-3′) and UK1-RT-021R (5′-GTGGGCACACAG-
AAGCAGCACTGC-3′), was subcloned into pCR2.1-
TOPO (Invitrogen), and was sequenced.
Expression of the puratrophin-1 gene in various hu-
man tissues was studied by RT-PCR with use of primers
UKI-RT-025F and UK1-RT-005R on human Multiple
Tissue Panels I and II (Clontech [BD Bioscience]). Ex-
pression levels of puratrophin-1 mRNA were compared
among control and patient cerebellar cortices by RT-
PCR with use of primers UK1-RT-BF001F (5′-TCA-
CGGTTCCCCGCGGCTCG-3′) and UK1-RT-BF019R
(5′-GGTTGCATGGCCCTGAGAGTCTGG-3′), which
yielded PCR products of 291, 419, and 505 bp, de-
pending on alternative transcription. To compare pur-
atrophin-1 mRNA levels more precisely, real-time RT-
PCR analysis was performed on four control (individuals
with AD) and two chromosome 16q22.1–linked ADCA
cerebella by use of TaqMan technique (Applied Biosys-
tems) on Applied Biosystems 7700 Sequence Detection
System. PCR was performed for total puratrophin-1
mRNAs (i.e., full-length and short-form mRNAs [Gen-
Bank accession numbers AB197663 and AB197664, re-
spectively]; definitions of these two isoforms are de-
scribed in the “Results” section) with primers total-taq-
F (5′-TGGAGAGATGAGTGTCAAGACTTTG-3′) and
total-taq-R (5′-AATGACTTGGGTCTGCCTTGG-3′).
The short-form puratrophin-1 mRNA was specifically
assessed with primers short-taq-F (5′-ATGCCACCGAC-
TGGAGATTT-3′) and short-taq-R (5′-GCTGCCCTGT-
AGCTCCTCAT-3′). The TaqMan probe for total pur-
atrophin-1 mRNA was 5′-FAM-CCAGATGCACGTTA-
AGGACCCAGGTC-TAMRA-3′, and that for short-
form puratrophin-1 mRNA was 5′-FAM-TCTCTGAC-
CCTACTCAGGCTGAAGCCC-TAMRA-3′. The exper-
iments were performed three times and were averaged.
The level of puratrophin-1 mRNA was assessed relative
to the level of G3PDH mRNA amplified with primers
supplied from the manufacturer (Applied Biosystems).
Since the expression level of G3PDH mRNA was
11,000-fold higher than that of puratrophin-1 mRNA,
one control individual was chosen and the value of pur-
atrophin-1 mRNA:G3PDH mRNA ratio (designated
“puratrophin-1 mRNA/G3PDH mRNA index”) was
standardized as “1”; another three control individuals
and two patients were compared relatively. The differ-
ence between the control and patient groups was statis-
tically analyzed with the Mann-Whitney U test.
To see the effect of the CrT change in the 5′ UTR of
puratrophin-1 gene on expression in vitro, the partial
5′-UTR fragment containing the mutation site was am-
plified with forward primers UK1-UF10-F2 (5′-CCG-
GAATTCCAGGCCTGAATTGCAGTTC-3′) and UK1-
UF10-R2 (5′-CCAGGCATCCCTGAAACT-3′) and was
subcloned into the HindIII-NcoI sites of the luciferase
assay vector, pGL3-Control Vector (Promega). The CrT
mutation was then generated by site-directed mutagene-
sis (Stratagene). Three types of vectors (mock, empty
pGL3-Control Vector; wild-type, pGL3 with normal
puratrophin-1 5′ UTR with allele C; and mutant, pGL3
with mutant puratrophin-1 5′ UTR with allele T) were
separately transfected with Renilla vector (Promega) into
HEK293 cells to equalize the transfection efficiency. The
transfection experiment was performed independently
three times. Luciferase activity (F/R: fire-fly luciferase
activity against Renilla activity) was assayed in accor-
dance with the manufacturer’s protocol and was statis-
tically analyzed with the Mann-Whitney U test.
Generation of Rabbit Polyclonal Antibodies
against Puratrophin-1
On the basis of the deduced amino acid sequence of
“full-length” and “short-form” puratrophin-1, the sec-
ondary structure of each isoform was predicted, and five
synthetic peptides were designed: polypeptide FL01 (aa
1–13), N-MERPLENGDESPD-C; FL02 (aa 421–432),
N-MDKADELYDRVD-C; FL03 (aa 570–583), N-EEG-
QRVLAELEQER-C; FL04 (aa 991–1003), N-RFEIW-
FRRRKARD-C; and SV01 (aa 13–26), N-REVWEGN-
GDAWRDE-C. The polypeptide FL01 lies at the amino
terminus of the puratrophin-1 (fig. 3). Therefore, the
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Figure 3 Genomic and mRNA structure of the puratrophin-1 gene. A, Intron-exon structure of puratrophin-1. Exons are shown as vertical
bars, and coding regions are shown in red. The CrT change at nt 4255 (or, 16 nt upstream of the translation initiation codon) is indicated.
Nucleotide numbers (indicated by a number sign [#]) are counted from the 5′ end. B, Puratrophin-1 mRNAs cloned from the human cerebellum.
Major transcripts are full-length and short-form puratrophin-1 mRNAs; minor transcripts (B1–B8) were also cloned. The CRL-TRIO, spectrin,
Rho GEF/DH, and PH domains are indicated. Epitopes for five rabbit anti–puratrophin-1 antibodies (FL01–FL04 and SV01) are also mapped.
Antibodies FL02, FL03, and FL04 are designed to specifically detect full-length puratrophin-1, the antibody SV01 specifically detects short-
form puratrophin-1, and the antibody FL01 detects both full-length and short-form puratrophin-1.
Figure 4 Immunoprecipitation of puratrophin-1–HA fusionpro-
tein and immunoabsorption test with antiserum against puratrophin-
1. The legend is available in its entirety in the online edition of The
American Journal of Human Genetics.
antibody Prtrphn1-Ab FL01 would detect both full-
length and short-form puratrophin-1. The polypeptides
FL02, FL03, and FL04 are specific for the full-length
puratrophin-1 (fig. 3). Notably, FL03 is at the spectrin
repeat motif. The polypeptide SV01 lies at the carboxyl-
terminus of the short-form puratrophin-1. Therefore, the
antibody Prtrphn1-Ab SV01 would specifically recog-
nize the short-form puratrophin-1. Each antigen was im-
munized into rabbit, and polyclonal antibodies were ob-
tained as described elsewhere (Ishikawa et al. 1999).
The specificity of Prtrhn1-Abs was assessed by detec-
tion of recombinant puratrophin-1 protein. For this pur-
pose, an antisense-strand primer was designed to encode
hemagglutinin A (HA) in-frame at the carboxyl-terminus
of the puratrophin-1. By PCR, full-length puratrophin-
1 cDNA with the HA-coding nucleotide sequence at its
3′ end was generated and was then cloned into pcDNA1
expression vector (Invitrogen). The puratrophin-1–HA
fusion protein, transiently expressed in HEK293 cells,
was first immunoprecipitated with Prtrhn1-Abs and then
was detected with rat monoclonal anti-HA High Affinity
antibody (3F10 [Roche Mannheim]) (fig. 4). The fusion
protein immunoprecipitated with preimmune sera was
not detected with anti-HA antibody.
Specificity of Prtrphn1-Abs on immunohistochemistry
was assessed by immunoabsorption test. Solutions con-
taining Prtrphn1-Ab and different concentrations of
antigen (synthetic peptide) (0, 0.01, 0.1, and 1 mg/
Ishikawa et al.: Gene for 16q22.1-Linked Ataxia 287
Figure 5 Southern-blot analysis. The legend is available in its
entirety in the online edition of The American Journal of Human
Genetics.
liter) were made. Sections were incubated overnight
with these solutions as other immunohistochemical
staining. Prtrphn1-Abs were completely absorbed by
peptides of higher concentrations (fig. 4).
Immunohistochemical Analyses of Puratrophin-1,
Golgi-Apparatus Protein G58K, and Spectrin in Control
Mouse, Human, and 16q22.1-Linked ADCA Tissues
Five polyclonal antibodies against puratrophin-1
(Prtrphn1-Ab types FL01, FL02, FL03, FL04, and
SV01) were used for immunohistochemistry. Mouse
monoclonal antibody against the microtubule-binding
peripheral Golgi-apparatus membrane protein G58K
(Sigma) and the mouse monoclonal antibody for a-
and b-spectrin (MAB372 [Chemicon International])
were also used for immunohistochemistry.
Formalin-fixed paraffin-embedded tissue sections were
prepared. Examined tissues were C57BL/6J wild-type
mouse tissue, including cochlea (1 d postnatal), normal-
control human tissues (testis, pancreas, prostate gland,
lung, liver, heart, kidney, and brain from three individ-
uals who died with nonneurological diseases), disease-
control human brains (AD [ ], SCA6 [ ], mul-np 3 np 2
tiple-system atrophy [MSA] [ ], and SCA3/MJDnp 3
[ ]), and three brains with chromosome 16q22.1–np 3
linked ADCA. Immunohistochemistry was performed
as described elsewhere (Ishikawa et al. 1999). In brief,
sections were incubated overnight with Prtrphn1-Abs
(diluted 1:200 with PBS), G58K (diluted 1:400), or
MAB372 (diluted 1:200) at 4C, after which the primary
antibody was serially detected with avidin-biotinylated
peroxidase complex method (Vector), was developed
with 3,3′-diaminobenzidine (DAB), and was counter-
stained with hematoxylin.
Results
Restriction of the Critical Interval to !600 kb
within Human Chromosome 16q22.1
Haplotype reconstruction of 10 informative families re-
vealed that all affected individuals in these families were
segregated with the haplotype 3-1-4-4-4 for markers
16cen-D16S421-TA001-GA001-TTTA001-CATG003-
16qter lying between GATA01 and 17msm (fig. 1). Ge-
notypes of all affected individuals in the remaining 42
families that were not informative enough for haplotype
reconstruction were also consistent with the common
haplotype. Particularly, a dinucleotide (GA) repeat marker
GA001 showed strong linkage disequilibrium: the allele
4 of GA001 was seen in all affected individuals in all
families with chromosome 16q22.1–linked ADCA,
whereas that allele was seen very rarely (frequency
0.1%) in 1,000 control chromosomes (fig. 1). Whereas
only one common haplotype was seen between GATA01
and 17msm, different alleles were seen for GATA01
and other centromeric markers or for 17msm and other
telomeric markers (fig. 1). These results indicate that the
gene for chromosome 16q22.1–linked ADCA is most
likely to exist in the interval between GATA01 and
17msm. This region was within the previously refined
intervals (Hellenbroich et al. 2003; Li et al. 2003) and
was considered to be !600 kb in size in the database
Ensembl.
Identification of a Single-Nucleotide Substitution
in the 5′ UTR of the Gene Encoding Puratrophin-1
in the Critical Interval
Within the critical interval between GATA01 and
17msm, 21 different genes were identified (fig. 2A). We
screened all 21 genes by direct sequencing of amplified
genomic PCR products of all coding exons and flanking
intronic sequences. Genomic Southern-blot analyses were
also performed but did not detect any rearrangement
(fig. 5).
We found that all patients with chromosome 16q22.1–
linked ADCA harbored a heterozygous CrT single-nu-
cleotide substitution at the position 16 nt upstream of the
putative translation initiation codon of the gene
Q9H7K4, encoding hypothetical protein DKFZP434I216
(NCBI accession number BC054486) (fig. 2B). All the at-
risk individuals who had the founder haplotype between
GATA01 and 17msm also harbored the CrT change. The
ages of these individuals were below the maximum age
at disease onset in their families, which indicates that they
could be in presymptomatic stages. On the other hand,
this CrT substitution was not seen in 500 healthy Jap-
anese individuals (1,000 chromosomes), confirmed by
EcoNI RFLP analysis (fig. 2C). All intronic sequences be-
tween the 21 exons and all the 8-kb sequences upstream
of the Q9H7K4 gene were also directly sequenced. Al-
though there was a GrA SNP 44 nt upstream of the 3′
splice site of intron 9 of the Q9H7K4 gene, the allele
segregating with the disease was also seen in 75% of
control chromosomes. As far as we examined, the CrT
change at the position 16 nt upstream of the putative
translation initiation codon of the gene Q9H7K4 was the
only specific change seen for patients with chromosome
16q22.1–linked ADCA. We renamed this protein “pur-
atrophin-1,” meaning Purkinje cell atrophy associated
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Figure 6 Puratrophin-1 mRNA expression in various control human tissues. With this nonquantitative RT-PCR analysis, a relatively
stronger expression was observed in the testis and pancreas, whereas mild or moderate expression was seen in the spleen, thymus, prostate
gland, heart, placenta, lung, liver, and kidney. Puratrophin-1 mRNA expression was low in the ovary, small intestine, colon, peripheral-blood
leukocytes, whole brain, and skeletal muscle.
protein-1. (We reserved the nomenclature “ataxin-4” for
families with original SCA4.)
Characterization of the Puratrophin-1 Gene and Its
Expression
The puratrophin-1 gene comprises 20 introns and 21
exons spanning a 13.7-kb genomic region (fig. 3A). RT-
PCR and RACE experiments revealed that this gene is
expressed in the human brain with an 8,561-nt mRNA
and a single ORF of 3,576 nt (from nt 4,271 to nt 7,846)
(fig. 3B). The first exon was 4,769 nt in length. This
“full-length” transcript is predicted to encode a 134-kD
protein, consisting of 1,192 aa, that contains four im-
portant domains: the cellular retinaldehyde-binding
(CRAL)/triple function domain (TRIO) (at codons 304–
338), the spectrin-repeat domain in the middle portion
(at codons 447–601), the guanine-nucleotide exchange
factor (GEF) for Rho/Rac/Cdc42-like GTPases followed
by the Dbl-homologous (Rho GEF/DH) domain (at co-
dons 733–907), and the pleckstrin-like homology (PH)
domain (at codons 921–1027). The presence of these
four domains suggests the role of puratrophin-1 in in-
tracellular signaling and actin dynamics targeted to the
Golgi apparatus (Godi et al. 1998; Fucini et al. 2000).
Besides the full-length puratrophin-1 mRNA, we also
found several alternative transcripts in human cerebellar
cDNA (fig. 3B). The most common one had an unspliced
intron 1 between exons 1 and 2 (“short-form” puratro-
phin-1 mRNA). This intron retention produced a frame-
shift after exon 1 that resulted in a premature stop codon
after 26 aa residues in intron 1. There were several other
alternative transcripts (B1–B8 [fig. 3B]) in addition to
full-length and short-form puratrophin-1 mRNA. How-
ever, expression levels of these transcripts were consid-
ered lower than those of full-length or short-form pur-
atrophin-1 mRNA, as judged from cloning frequencies.
Puratrophin-1 mRNA was expressed in many tissues with
various expression levels (fig. 6). The strongest expres-
sion was observed in the testis and pancreas, whereas
its expression level was low in the “whole” brain. The
expression was very weak on northern-blot analysis,
even in the testis and pancreas (data available on re-
quest), which indicates that the expression of puratro-
phin-1 mRNA was not abundant.
The Consequence of a CrT Change for Puratrophin-1
mRNA Expression
The consequence of the CrT change in the puratro-
phin-1 gene was assessed by RT-PCR on frozen cere-
bellar tissues of two patients. No aberrant puratrophin-
1 mRNA was detected, which indicates that the muta-
tion in the 5′ UTR does not affect alternative transcrip-
Figure 7 The consequence of a CrT change in the 5′ UTR of puratrophin-1 mRNA. A, The puratrophin-1 mRNA level assessed relative
to G3PDH mRNA levels. The puratrophin-1 mRNA levels in the cerebella of individuals with chromosome 16q22.1–linked ADCA appear
slightly decreased compared with levels in control individuals. B, Quantitative analysis of puratrophin-1 mRNA, with the use of the TaqMan
technique in cerebellar mRNAs of four control individuals (with AD) and of two individuals with chromosome 16q22.1–linked ADCA. Both
total puratrophin-1 mRNA (i.e., full-length and short-form mRNAs) and short-form puratrophin-1 mRNAs tended to be reduced in cerebella
of individuals with chromosome 16q22.1–linked ADCA, although the significance was not statistically proven ( for total mRNA;Pp .0641
for short-form mRNA). C, Histogram of in vivo luciferase assay. “F/R” denotes fire-fly luciferase activity versus Renilla activity.Pp .1649
The wild-type construct with allele C increases luciferase expression compared with an empty vector (Mock), whereas the mutant construct
with allele T demonstrates significantly reduced luciferase activity ( ).P ! .001
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Figure 8 Expression of puratrophin-1 in control human and mouse tissues. A and B, Human testis. C and D, Human prostate gland. E
and F, Human pancreas. G and H, Human kidney. I and J, Mouse cochlea. A, C, E, G, and I, Immunohistochemical analysis with use of the
polyclonal anti–puratrophin-1 antibody SV01. B, D, F, H, and J, Hematoxylin and eosin stain of the section adjacent to that shown in A, C,
E, G, and I, respectively. Puratrophin-1 is expressed in many tissues, with varying strength. In particular, Leydig cells in the testis (arrow in
A), epithelial cells in the prostate gland (C), and Langerhans islet in the pancreas (E) showed strong immunoreactivity. Immunoreactivity in
the kidney was weak (G). Expression in the cochlea was particularly intense at the sensory hairlets (arrow in I). Hair cells of the stria vascularis
also showed immunoreactivity (arrowhead in I). All scale bars p 50 mm.
tion significantly. Instead, the expression level of pura-
trophin-1 mRNA in the patient cerebella appeared slightly
low compared with that in control cerebella (fig. 7A).
On real-time RT-PCR analysis by TaqMan technique,
the expression of puratrophin-1 mRNA in the patient
cerebella appeared lower than that in the control samples
(fig. 7B). The tendency of reduction was seen for both
total and short-form puratrphin-1 mRNAs, although the
significance was not proven statistically ( forPp .0641
total puratrophin-1 mRNA; for short-formPp .1649
puratrophin-1 mRNA).
The in vitro study with puratrophin-1 5′-UTR se-
quences subcloned into luciferase expression vectors
showed significantly reduced luciferase activity; the con-
struct had mutant allele T, and the wild-type construct
had allele C (fig. 7C). These data suggest that the CrT
change in the puratrophin-1 5′ UTR could lead to re-
duced mRNA expression.
Expression of Puratrophin-1 in Control Human
and Mouse Tissues and in Brains of Patients
with 16q22.1–Linked ADCA
We next examined puratrophin-1 expression by im-
munohistochemistry using rabbit polyclonal Prtrhn1-
Abs. Puratrophin-1 expression was seen in many control
human tissues and mouse cochlea (fig. 8). Interestingly,
puratrophin-1 expression was commonly seen in epithe-
lial cells, such as epithelial cells in the human testis and
hair cells in the mouse cochlea. As far as we examined
in human tissues, the strength of immunoreactivity cor-
related with the mRNA expression level revealed by RT-
PCR experiments (fig. 6).
In control human brains, both full-length and short-
form puratrophin-1 was expressed faithfully in various
neurons but most strongly in Purkinje cells (fig. 9A). In
chromosome 16q22.1–linked ADCA brains, a striking
difference was noted: the presence of microscopic ag-
gregates of puratrophin-1 in the cytoplasm of Purkinje
cells (fig. 9B). These aggregates were detected with all
Prtrhn1-Abs, which indicates that full-length puratro-
phin-1 and short-form puratrophin-1 were both in-
volved in the aggregate. On the other hand, puratrophin-
1 aggregates were not obvious in neurons other than
Purkinje cells. The finding of puratrophin-1 aggregates
was specific to chromosome 16q22.1–linked ADCA
brains, since the aggregates were not seen in other dis-
eases showing degeneration of Purkinje cells, such as
SCA6 or MSA.
We next examined the expression of G58K and of the
a- and b-spectrin on control and chromosome 16q22.1–
linked ADCA brains. Whereas G58K and spectrin were
homogeneously stained in control brains (fig. 9C and
9E), these proteins both formed aggregation within the
Purkinje cell of chromosome 16q22.1–linked ADCA
brains (fig. 9D and 9F). This further suggests that for-
mation of puratrophin-1 aggregates is abnormal and
associates with disturbances of Golgi apparatus and
spectrin.
Discussion
The single-nucleotide CrT substitution in the 5′ UTR of
the puratrophin-1 gene is strongly associated with chro-
mosome 16q22.1–linked ADCA, as evidenced by the fol-
lowing three points. First, this single-nucleotide change
was the only specific difference detected in patients, as
far as we screened all exons and intron-exon boundaries
of the 21 annotated genes lying within the founder chro-
mosome. The change completely segregated with the dis-
ease in 52 unrelated families that originated in all sec-
tions of Japan, whereas such a change was not seen in
1,000 control chromosomes. We also screened for ge-
nomic rearrangement by Southern-blot analysis, but we
did not observe any changes. Second, the CrT change
was not a mere polymorphism present in the founder
chromosome, since it resulted in reduced expression in
the in vitro luciferase assay. Consistently, tendency for
reduction in mRNA expression was seen in the cerebel-
lum of chromosome 16q22.1–linked ADCA. Third, pur-
atrophin-1 was aggregated in the major target neuron
(i.e., the Purkinje cell) of chromosome 16q22.1–linked
ADCA. The Golgi-apparatus membrane protein (G58K)
and spectrin, both important cytoskeletal proteins, were
also aggregated. Since aggregation of mutated protein is
a common feature of many neurodegenerative disorders
(Ross and Poirier 2004), a single-nucleotide change in
the 5′ UTR in the puratrophin-1 gene appears to be the
mutation that causes chromosome 16q22.1–linked
ADCA. Most mutations that cause ADCAs reside in
genes encoding proteins whose functions are not well
understood, except for the a1A-calcium channel
(Cav2.1) for SCA6 (Zhuchenko et al. 1997), PKCg for
Figure 9 Immunohistochemical analysis of puratrophin-1, Golgi-apparatus membrane protein (G58K), and spectrin in control cells and
samples from a patient’s cerebellum. A, Puratrophin-1 expression in the cell body of Purkinje cells, visualized with use of rabbit polyclonal
anti–puratrophin-1 antibody (FL01). B, With use of same antibody FL01, aggregation of puratrophin-1 (arrow), seen in a Purkinje cell of a
brain affected with chromosome 16q22.1–linked ADCA. C, G58K expression, seen diffusely in the cell body of control Purkinje cells. D, G58K
aggregation (arrow), morphologically quite similar to the puratrophin-1 aggregate, seen in a patient’s Purkinje cell. E, Spectrin expression, seen
in the cell body of a control Purkinje cell. F, Spectrin aggregation in a patient’s Purkinje cell. All scale bars p 50 mm.
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SCA14 (Chen et al. 2003), TATA-binding protein for
SCA17 (Koide et al. 1999), and FGF14 for ADCA with
FGF14 mutation (van Swieten et al. 2003). Puratrophin-
1 is the first known protein related to intracellular sig-
naling and cytoskeleton that is associated with ADCA.
Our preliminary results suggest that the frequency of
chromosome 16q22.1–linked ADCA is relatively high,
since it was ranked the third most frequent ADCA in
Japan, after MJD/SCA3 and SCA6. Since chromosome
16q22.1–linked ADCA had a strong founder effect, it
will be important to clarify whether this specific CrT
change is seen in other ethnic groups. Particularly, it is
extremely important to clarify whether original patients
with SCA4 reported from North American and German
populations harbor mutation within the puratrophin-1
gene (Flanigan et al. 1996; Hellenbroich et al. 2003).
A heterozygous, single-nucleotide substitution in the
5′ UTR that is associated with aggregation of the gene
product is a unique feature as a cause of human disease.
Generally, a single-nucleotide substitution in the 5′ UTR
may result in expression of aberrant mRNA, abnormal
trafficking of mutant transcripts due to conformational
changes, or reduced transcription of mRNA, as in b
thalassemia intermedia (Sgourou et al. 2004). In the
present study, no aberrant transcripts were cloned from
patient brains. Instead, the result from the in vitro study
suggested that the transcription efficiency could be re-
duced significantly by the CrT substitution in the 5′
UTR of the puratrophin-1 gene. Consistent with this in
vitro finding, levels of puratrophin-1 mRNA tended to
be lower in cerebella of patients with 16q22.1-linked
ADCA than in those of AD-affected controls. Further
studies comprising a larger number of samples that in-
clude “neurologically normal” controls will be neces-
sary to confirm that reduced puratrophin-1 mRNA ex-
pression is associated with the CrT change in the 5′
UTR. Although aggregations of mutated proteins in
most neurodegenerative diseases are due to conforma-
tional changes produced by amino acid alterations, re-
duced protein expression may also cause protein ag-
gregation, such as the neurofilament light-chain aggre-
gation in anterior horn cells of patients with amyotro-
phic lateral sclerosis (ALS) (Bergeron et al. 1994). It is
currently not known how the CrT change in the pur-
atrophin-1 gene leads to puratrophin-1 aggregation.
However, it is possible that alteration in the stoichiometry
or changes in the protein stability, observed in neuro-
filament proteins in ALS (Ge et al. 2003), also exist for
puratrophin-1 in chromosome 16q22.1–linked ADCA.
In addition, it should be noted that since reduction of
puratrophin-1 mRNA levels in patient cerebella was
small, that may not be a sufficient explanation of the
formation of aggregation. It will be important to assess
the puratrophin-1 mRNA levels specifically in Purkinje
cells, where the protein aggregates.
Puratrophin-1 is a novel protein with four important
domains: the spectrin repeat, CRAL/TRIO, Rho GEF/
DH, and PH domains. Therefore, the puratrophin-1
gene would be the fifth gene that encodes Rho GEF
protein to be associated with human disease, after the
FGD1GEF gene for faciogenital dysplasia (Pasteris et
al. 1994), the ARHGEF6 gene for X-linked nonsyn-
dromic mental retardation (Kutsche et al. 2000), the
ARHGEF10 gene for autosomal dominant neuropathy
with thin myelinated fibers (Verhoeven et al. 2003), and
the ALS2 gene for the autosomal recessive juvenile mo-
tor neuron disease ALS2 (Hadano et al. 2001; Yang et
al. 2001). GEFs exert diverse functions in intracellular-
membrane trafficking and microtubule dynamics and
ultimately regulate numerous cellular responses—such
as proliferation, differentiation, and movement—by ac-
tivating small G-protein GTPases (Rossman et al. 2005).
Although Rho GEF/DH and PH domains are typical for
Rho GEF proteins, the presence of a spectrin repeat
suggests that puratrophin-1 could be targeted to the
Golgi-apparatus membrane, where it may regulate cer-
tain membrane dynamics through modulating actin
(Godi et al. 1998; Lemmon et al. 2002). The CRAL/
TRIO domain is implicated in the nerve growth factor
(NGF) pathway that leads to neurite outgrowth through
activating Rho G (Estrach et al. 2002), which indicates
that puratrophin-1 may also have a role in cell differ-
entiation signaling through NGF. In the present study,
we showed that the Golgi-apparatus membrane protein
and spectrin both form aggregation in the Purkinje cells
of patient brains, which strongly supports the hypothe-
sis that puratrophin-1 indeed interacts with these es-
sential cytoskeletons. Formation of these aggregations,
which seems to be a new phenomenon implicated in
pathogenesis of human disease, could be deleterious for
cells, since Golgi-apparatus membrane proteins and spec-
trin are important in maintaining cellular architecture,
as noted for autosomal dominant polycystic kidney dis-
eases (Charron et al. 2000). In addition, it also seems
rational to speculate that disturbance of puratrophin-1
may affect Purkinje-cell morphology and eventually
cause the peculiar Purkinje-cell atrophy that character-
izes chromosome 16q22.1–linked ADCA, since Rho
GEFs are implicated particularly in neural morphogene-
sis and connectivity by regulating actin dynamics (Godi
et al. 1998).
Finally, the association of progressive hearing im-
pairment in patients with chromosome 16q22.1–linked
ADCA may suggest a role of puratrophin-1 in hearing.
As far as we were able to examine by auditory tests,
42.8% of study families had hearing impairment. Au-
diometric configurations showing mid-frequency U-
shaped or flat-shaped pattern also suggested that the
hearing impairment of these patients was not a simple
age-related hearing loss. However, it should be noted
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that some families had moderate hearing impairment,
whereas other families had only mild hearing impair-
ment, which may indicate the presence of other modi-
fying genetic factors for this phenotype. Further clinical
analyses with use of detailed auditory tests are needed
to ascertain how strongly hearing impairment is asso-
ciated with ataxia. If hearing impairment is confirmed
as being complicated by chromosome 16q22.1–linked
ADCA, puratrophin-1 will be the first deafness/hearing-
impairment protein related to Rho GEF. Since mutations
in the g-actin gene (ACTG1; DFN20/26) (Zhu et al.
2003), genes coding proteins that interact with actin
(e.g., the myosins espin and harmonin), or a gene coding
proteins that coordinate actin polymerization (Mburu
et al. 2003) are known to cause deafness, it is possible
that puratrophin-1 disruption causes hearing impair-
ment by disturbing actin dynamics in the cochlea. In
support of this hypothesis, expression of puratrophin-
1 was seen in mouse cochlear hair cells, in which actin
is also expressed (Mburu et al. 2003). Rho GTPases are
also important regulators of actin cytoskeleton in stereo-
cilia development, which is crucial for auditory trans-
duction (Kollmar 2001). We hypothesize that the pur-
atrophin-1 gene mutation ultimately causes hearing im-
pairment by dysregulation of actin in the cochlea. Fur-
ther studies, such as targeted disruption of puratrophin-
1 in mouse, will be important for clarifying whether
puratrophin-1 has a role in hearing.
In summary, we have identified that a single-nucleo-
tide CrT substitution in the 5′ UTR of the gene pur-
atrophin-1 is strongly associated with chromosome
16q22.1–linked ADCA. If patients with SCA4 are found
to harbor mutations in this gene, it would suggest that
the chromosome 16q22.1–linked ADCA in Japan is al-
lelic with SCA4. Identification of the mechanism of pur-
atrophin-1 expression, the upstream signaling cascade
that activates puratrophin-1, and the actual Rho
GTPase activated by puratrophin-1 would be the next
key steps for understanding the molecular mechanisms
that underlie cellular degeneration of chromosome
16q22.1–linked ADCA and hearing impairment.
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